메뉴 건너뛰기




Volumn 10, Issue 9, 2015, Pages

Continued follow-up of Phambili phase 2b randomized HIV-1 vaccine trial participants supports increased HIV-1 acquisition among vaccinated men

(18)  Moodie, Zoe a   Metch, Barbara a   Bekker, Linda Gail b   Churchyard, Gavin c,d,e   Nchabeleng, Maphoshane f   Mlisana, Koleka h   Laher, Fatima i   Roux, Surita b   Mngadi, Kathryn g,h   Innes, Craig c   Mathebula, Matsontso f   Allen, Mary j   Bentley, Carter a   Gilbert, Peter B a   Robertson, Michael k   Kublin, James a   Corey, Lawrence a   Gray, Glenda E i,l  


Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

EID: 84947474577     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137666     Document Type: Article
Times cited : (29)

References (23)
  • 2
    • 33845433434 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    • 17109337
    • Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. The Journal of infectious diseases. 2006; 194 (12):1661-71. doi: 10.1086/508748 PMID: 17109337.
    • (2006) The Journal of Infectious Diseases , vol.194 , Issue.12 , pp. 1661-1671
    • Pitisuttithum, P.1    Gilbert, P.2    Gurwith, M.3    Heyward, W.4    Martin, M.5    Van Griensven, F.6
  • 3
    • 13944254982 scopus 로고    scopus 로고
    • Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
    • 15688278
    • Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. The Journal of infectious diseases. 2005; 191(5):654-65. doi: 10.1086/428404 PMID: 15688278.
    • (2005) The Journal of Infectious Diseases , vol.191 , Issue.5 , pp. 654-665
    • Flynn, N.M.1    Forthal, D.N.2    Harro, C.D.3    Judson, F.N.4    Mayer, K.H.5    Para, M.F.6
  • 4
    • 84887865083 scopus 로고    scopus 로고
    • Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine
    • 24099601 Epub 2013/10/09. PubMed Central PMCID: PMC4030634
    • Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013; 369(22):2083-92. Epub 2013/10/09. doi: 10.1056/NEJMoa1310566 PMID: 24099601; PubMed Central PMCID: PMC4030634.
    • (2013) N Engl J Med. , vol.369 , Issue.22 , pp. 2083-2092
    • Hammer, S.M.1    Sobieszczyk, M.E.2    Janes, H.3    Karuna, S.T.4    Mulligan, M.J.5    Grove, D.6
  • 5
    • 56649105122 scopus 로고    scopus 로고
    • Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial
    • 19012954 PubMed Central PMCID: PMC2721012
    • Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008; 372(9653):1881-93. doi: 10.1016/S0140-6736(08)61591-3 PMID: 19012954; PubMed Central PMCID: PMC2721012.
    • (2008) Lancet , vol.372 , Issue.9653 , pp. 1881-1893
    • Buchbinder, S.P.1    Mehrotra, D.V.2    Duerr, A.3    Fitzgerald, D.W.4    Mogg, R.5    Li, D.6
  • 6
    • 84899445004 scopus 로고    scopus 로고
    • Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: Unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study
    • 24560541 Epub 2014/02/25. PubMed Central PMCID: PMC4174314
    • Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014; 14(5):388-96. Epub 2014/02/25. doi: 10.1016/S1473-3099(14)70020-9 PMID: 24560541; PubMed Central PMCID: PMC4174314.
    • (2014) Lancet Infect Dis. , vol.14 , Issue.5 , pp. 388-396
    • Gray, G.E.1    Moodie, Z.2    Metch, B.3    Gilbert, P.B.4    Bekker, L.G.5    Churchyard, G.6
  • 7
    • 84874433635 scopus 로고    scopus 로고
    • Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity
    • 23151505 PubMed Central PMCID: PMC3528489
    • Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(50):E3503-12. doi: 10.1073/pnas.1208972109 PMID: 23151505; PubMed Central PMCID: PMC3528489.
    • (2012) Proceedings of the National Academy of Sciences of the United States of America , vol.109 , Issue.50 , pp. E3503-E3512
    • Zak, D.E.1    Andersen-Nissen, E.2    Peterson, E.R.3    Sato, A.4    Hamilton, M.K.5    Borgerding, J.6
  • 8
    • 78149417692 scopus 로고    scopus 로고
    • Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: A randomized clinical trial (HVTN 054)
    • 21048953 PubMed Central PMCID: PMC2965084
    • Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, et al. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PloS one. 2010; 5(10):e13579. doi: 10.1371/journal.pone.0013579 PMID: 21048953; PubMed Central PMCID: PMC2965084.
    • (2010) PLoS One , vol.5 , Issue.10 , pp. e13579
    • Peiperl, L.1    Morgan, C.2    Moodie, Z.3    Li, H.4    Russell, N.5    Graham, B.S.6
  • 9
    • 77958498605 scopus 로고    scopus 로고
    • Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa
    • 20877623 PubMed Central PMCID: PMC2943475
    • Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PloS one. 2010; 5(9):e12873. doi: 10.1371/journal.pone.0012873 PMID: 20877623; PubMed Central PMCID: PMC2943475.
    • (2010) PLoS One , vol.5 , Issue.9 , pp. e12873
    • Jaoko, W.1    Karita, E.2    Kayitenkore, K.3    Omosa-Manyonyi, G.4    Allen, S.5    Than, S.6
  • 10
    • 79955774295 scopus 로고    scopus 로고
    • Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults
    • 20854108 PubMed Central PMCID: PMC3422055
    • Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, et al. Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS research and human retroviruses. 2010. doi: 10.1089/AID.2010.0151 PMID: 20854108; PubMed Central PMCID: PMC3422055.
    • (2010) AIDS Research and Human Retroviruses
    • Nicholson, O.1    Dicandilo, F.2    Kublin, J.3    Sun, X.4    Quirk, E.5    Miller, M.6
  • 11
    • 75749141272 scopus 로고    scopus 로고
    • A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)
    • 20078213 PubMed Central PMCID: PMC2811694
    • Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). The Journal of infectious diseases. 2010; 201(4):600-7. doi: 10.1086/650299 PMID: 20078213; PubMed Central PMCID: PMC2811694.
    • (2010) The Journal of Infectious Diseases , vol.201 , Issue.4 , pp. 600-607
    • Kibuuka, H.1    Kimutai, R.2    Maboko, L.3    Sawe, F.4    Schunk, M.S.5    Kroidl, A.6
  • 12
    • 79961048088 scopus 로고    scopus 로고
    • A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)
    • 21857901 PubMed Central PMCID: PMC3152265
    • Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PloS one. 2011; 6(8):e21225. doi: 10.1371/journal.pone.0021225 PMID: 21857901; PubMed Central PMCID: PMC3152265.
    • (2011) PLoS One , vol.6 , Issue.8 , pp. e21225
    • Churchyard, G.J.1    Morgan, C.2    Adams, E.3    Hural, J.4    Graham, B.S.5    Moodie, Z.6
  • 13
    • 69749111528 scopus 로고    scopus 로고
    • Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults
    • 19605598 PubMed Central PMCID: PMC2745015
    • Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, et al. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clinical and vaccine immunology: CVI. 2009; 16 (9):1285-92. doi: 10.1128/CVI.00144-09 PMID: 19605598; PubMed Central PMCID: PMC2745015.
    • (2009) Clinical and Vaccine Immunology: CVI , vol.16 , Issue.9 , pp. 1285-1292
    • Harro, C.1    Sun, X.2    Stek, J.E.3    Leavitt, R.Y.4    Mehrotra, D.V.5    Wang, F.6
  • 14
    • 66149156475 scopus 로고    scopus 로고
    • Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials
    • 19339347 PubMed Central PMCID: PMC2687372
    • Koup RA, Lamoreaux L, Zarkowsky D, Bailer RT, King CR, Gall JG, et al. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. Journal of virology. 2009; 83(12):6318-22. doi: 10.1128/JVI.00384-09 PMID: 19339347; PubMed Central PMCID: PMC2687372.
    • (2009) Journal of Virology , vol.83 , Issue.12 , pp. 6318-6322
    • Koup, R.A.1    Lamoreaux, L.2    Zarkowsky, D.3    Bailer, R.T.4    King, C.R.5    Gall, J.G.6
  • 15
    • 60549106905 scopus 로고    scopus 로고
    • Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults
    • 19108693 PubMed Central PMCID: PMC3256563
    • Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS research and human retroviruses. 2009; 25(1):103-14. doi: 10.1089/aid.2008.0212 PMID: 19108693; PubMed Central PMCID: PMC3256563.
    • (2009) AIDS Research and Human Retroviruses , vol.25 , Issue.1 , pp. 103-114
    • Harro, C.D.1    Robertson, M.N.2    Lally, M.A.3    O'Neill, L.D.4    Edupuganti, S.5    Goepfert, P.A.6
  • 16
    • 84862904805 scopus 로고    scopus 로고
    • Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)
    • 22561365 Epub 2012/05/09. PubMed Central PMCID: PMC3490694
    • Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis. 2012; 206(2):258-66. Epub 2012/05/09. doi: 10.1093/infdis/jis342 PMID: 22561365; PubMed Central PMCID: PMC3490694.
    • (2012) J Infect Dis. , vol.206 , Issue.2 , pp. 258-266
    • Duerr, A.1    Huang, Y.2    Buchbinder, S.3    Coombs, R.W.4    Sanchez, J.5    Del Rio, C.6
  • 17
    • 79959301474 scopus 로고    scopus 로고
    • Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of-concept phase 2b study
    • 21570355 PubMed Central PMCID: PMC3417349
    • Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. The Lancet Infectious diseases. 2011; 11 (7):507-15. doi: 10.1016/S1473-3099(11)70098-6 PMID: 21570355; PubMed Central PMCID: PMC3417349.
    • (2011) The Lancet Infectious Diseases , vol.11 , Issue.7 , pp. 507-515
    • Gray, G.E.1    Allen, M.2    Moodie, Z.3    Churchyard, G.4    Bekker, L.G.5    Nchabeleng, M.6
  • 18
    • 62749200441 scopus 로고    scopus 로고
    • Host immune responses to chronic adenovirus infections in human and nonhuman primates
    • 19116257 PubMed Central PMCID: PMC2648267
    • Calcedo R, Vandenberghe LH, Roy S, Somanathan S, Wang L, Wilson JM. Host immune responses to chronic adenovirus infections in human and nonhuman primates. Journal of virology. 2009; 83 (6):2623-31. doi: 10.1128/JVI.02160-08 PMID: 19116257; PubMed Central PMCID: PMC2648267.
    • (2009) Journal of Virology , vol.83 , Issue.6 , pp. 2623-2631
    • Calcedo, R.1    Vandenberghe, L.H.2    Roy, S.3    Somanathan, S.4    Wang, L.5    Wilson, J.M.6
  • 19
    • 84860390074 scopus 로고    scopus 로고
    • Adenovirus type 5 induces Vitamin A-metabolizing enzymes in dendritic cells and enhances priming of gut-homing CD8 T cells
    • 21289616 PubMed Central PMCID: PMC3097311
    • Ganguly S, Manicassamy S, Blackwell J, Pulendran B, Amara RR. Adenovirus type 5 induces vitamin A-metabolizing enzymes in dendritic cells and enhances priming of gut-homing CD8 T cells. Mucosal immunology. 2011; 4(5):528-38. doi: 10.1038/mi.2011.1 PMID: 21289616; PubMed Central PMCID: PMC3097311.
    • (2011) Mucosal Immunology , vol.4 , Issue.5 , pp. 528-538
    • Ganguly, S.1    Manicassamy, S.2    Blackwell, J.3    Pulendran, B.4    Amara, R.R.5
  • 20
    • 73949119632 scopus 로고    scopus 로고
    • Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1
    • 19918060 PubMed Central PMCID: PMC2785271
    • Benlahrech A, Harris J, Meiser A, Papagatsias T, Hornig J, Hayes P, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(47):19940-5. doi: 10.1073/pnas.0907898106 PMID: 19918060; PubMed Central PMCID: PMC2785271.
    • (2009) Proceedings of the National Academy of Sciences of the United States of America , vol.106 , Issue.47 , pp. 19940-19945
    • Benlahrech, A.1    Harris, J.2    Meiser, A.3    Papagatsias, T.4    Hornig, J.5    Hayes, P.6
  • 21
    • 84914695671 scopus 로고    scopus 로고
    • Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development
    • 25349379 PubMed Central PMCID: PMC4226080
    • Lewis GK, DeVico AL, Gallo RC. Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(44):15614-21. doi: 10.1073/pnas.1413550111 PMID: 25349379; PubMed Central PMCID: PMC4226080.
    • (2014) Proceedings of the National Academy of Sciences of the United States of America , vol.111 , Issue.44 , pp. 15614-15621
    • Lewis, G.K.1    DeVico, A.L.2    Gallo, R.C.3
  • 22
    • 77955430749 scopus 로고    scopus 로고
    • Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa
    • 20588163 PubMed Central PMCID: PMC2914808
    • Cohen CR, Moscicki AB, Scott ME, Ma Y, Shiboski S, Bukusi E, et al. Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. Aids. 2010; 24(13):2069-74. doi: 10.1097/QAD.0b013e32833c323b PMID: 20588163; PubMed Central PMCID: PMC2914808.
    • (2010) AIDS , vol.24 , Issue.13 , pp. 2069-2074
    • Cohen, C.R.1    Moscicki, A.B.2    Scott, M.E.3    Ma, Y.4    Shiboski, S.5    Bukusi, E.6
  • 23
    • 84907494055 scopus 로고    scopus 로고
    • The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier
    • 25268493 PubMed Central PMCID: PMC4182607
    • Lemos MP, Lama JR, Karuna ST, Fong Y, Montano SM, Ganoza C, et al. The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier. PloS one. 2014; 9(9):e108954. doi: 10.1371/journal.pone.0108954 PMID: 25268493; PubMed Central PMCID: PMC4182607.
    • (2014) PLoS One , vol.9 , Issue.9 , pp. e108954
    • Lemos, M.P.1    Lama, J.R.2    Karuna, S.T.3    Fong, Y.4    Montano, S.M.5    Ganoza, C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.